{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363388843626326272.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1152/ajprenal.00258.2017"}},{"identifier":{"@type":"URI","@value":"https://www.physiology.org/doi/pdf/10.1152/ajprenal.00258.2017"}}],"dc:title":[{"@value":"Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p> The incretin hormone, glucagon-like peptide-1 (GLP-1), is known for responding to dietary fat and carbohydrate. It elicits effects on pancreas, gut, and brain to stabilize blood glucose levels. We have previously reported that the GLP-1 agonist, exenatide, vasodilates the kidney and suppresses proximal reabsorption. The present study was undertaken to determine whether the renal effects of exenatide are mediated by nitric oxide (NO) and/or prostaglandins. Inulin clearance (glomerular filtration rate, GFR) and urine flow rate (UV) were measured in anesthetized rats before and during exenatide infusion (1 nmol/h iv). Animals were pretreated with cyclooxygenase (COX) inhibitor (meclofenamate), NO synthase (NOS) inhibitor ( N<jats:sup>G</jats:sup>-monomethyl-l-arginine, l-NMMA), NO clamp (l-NMMA + sodium nitroprusside), or placebo. Effectiveness of COX inhibition was tested by measuring urinary prostaglandin E<jats:sub>2</jats:sub> (UPGE<jats:sub>2</jats:sub>). Effectiveness of NOS blockade and NO clamp was determined by urinary NO degradation products (UNOx). Exenatide increased GFR, UV, UPGE<jats:sub>2</jats:sub>, and UNOx. Pretreatment with meclofenamate reduced UPGE<jats:sub>2</jats:sub> by 75% and reduced the effect of exenatide on UPGE<jats:sub>2</jats:sub> by 30% but did not modify the effects of exenatide on GFR or UV. Pretreatment with l-NMMA reduced UNOx and the impact of exenatide on GFR and UV by 50%. Pretreatment by NO clamp did not prevent UNOx from increasing during exenatide but blunted the effects of exenatide on GFR and UV. In conclusion, exenatide is a potent renal vasodilator and diuretic in the rat. These effects of exenatide are insensitive to COX inhibition but are mediated, in part, by NO. </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383388843626326144","@type":"Researcher","foaf:name":[{"@value":"Scott C. Thomson"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, University of California and VA San Diego Healthcare System, San Diego, California; and"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388843626326273","@type":"Researcher","foaf:name":[{"@value":"Ali Kashkouli"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, Emory University, Atlanta, Georgia"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388843626326272","@type":"Researcher","foaf:name":[{"@value":"Zhi Zhao Liu"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, University of California and VA San Diego Healthcare System, San Diego, California; and"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388843626326274","@type":"Researcher","foaf:name":[{"@value":"Prabhleen Singh"}],"jpcoar:affiliationName":[{"@value":"Department of Medicine, University of California and VA San Diego Healthcare System, San Diego, California; and"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"1931857X"},{"@type":"EISSN","@value":"15221466"}],"prism:publicationName":[{"@value":"American Journal of Physiology-Renal Physiology"}],"dc:publisher":[{"@value":"American Physiological Society"}],"prism:publicationDate":"2017-10-01","prism:volume":"313","prism:number":"4","prism:startingPage":"F854","prism:endingPage":"F858"},"reviewed":"false","url":[{"@id":"https://www.physiology.org/doi/pdf/10.1152/ajprenal.00258.2017"}],"createdAt":"2017-07-19","modifiedAt":"2019-09-08","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/2050588892104608640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1152/ajprenal.00258.2017"},{"@type":"CROSSREF","@value":"10.1007/s10157-020-02007-2_references_DOI_KSMy4k9K4msTdoMFsfizhkvu9kS"}]}